CELADON PHARMACEUTICALS PLC Logo

CELADON PHARMACEUTICALS PLC

Vertically integrated pharma developing cannabis medicines for chronic pain.

CEL | IL

Overview

Corporate Details

ISIN(s):
GB00BDQYGP38
LEI:
213800YXCATORT475807
Country:
United Kingdom
Address:
32-33 COWCROSS STREET, EC1M 6DF LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celadon Pharmaceuticals PLC is a vertically integrated pharmaceutical company focused on the research, cultivation, manufacturing, and commercial sale of cannabis-based medicines. The company's primary target market is chronic pain, aiming to provide alternatives to traditional treatments. It operates a licensed, 100,000 sq ft, EU-GMP certified facility for the indoor cultivation of high-THC cannabis and the extraction of Active Pharmaceutical Ingredients (API). A key differentiator is its MHRA-conditionally approved clinical trial for chronic pain, which seeks to generate robust data for potential reimbursement by national health services. Founded in 2018, Celadon is also engaged in R&D to generate novel intellectual property and develop a pipeline of prescription medicines for various conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-28 17:10
Post-Annual General Meeting Information
Result of General Meeting
English 20.4 KB
2025-07-02 08:00
Pre-Annual General Meeting Information
Proposed Cancellation
English 99.3 KB
2025-07-01 12:48
Capital/Financing Update
Funding Update
English 10.8 KB
2025-07-01 09:20
Post-Annual General Meeting Information
Result of AGM
English 24.0 KB
2025-06-30 08:00
Report Publication Announcement
Funding and Operational Update, Delay in Results
English 22.5 KB
2025-06-11 08:00
Capital/Financing Update
New Committed Credit Facility
English 14.2 KB
2025-06-06 16:55
Regulatory News Service
Funding Update, Notice of AGM
English 12.1 KB
2025-05-30 19:07
Capital/Financing Update
Funding Update
English 11.3 KB
2025-03-19 08:00
Capital/Financing Update
Funding Update
English 11.8 KB
2025-02-26 14:00
Capital/Financing Update
New Committed Credit Facility
English 15.5 KB
2025-02-12 08:00
Capital/Financing Update
Finance Update
English 10.4 KB
2025-01-31 08:00
Capital/Financing Update
Finance Update
English 10.7 KB
2025-01-16 08:00
Regulatory News Service
Update on Strategic Collaboration
English 13.7 KB
2025-01-02 08:00
Capital/Financing Update
Funding Update
English 10.6 KB
2024-12-20 08:00
Capital/Financing Update
Finance Update
English 10.8 KB

Automate Your Workflow. Get a real-time feed of all CELADON PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CELADON PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG
Galderma Group AG Logo
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland GALD

Talk to a Data Expert

Have a question? We'll get back to you promptly.